Results 101 to 110 of about 34,942 (245)

Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

Clinical Pharmacology &Therapeutics, EarlyView.
NAT2 encodes arylamine N‐acetyltransferase 2, a key enzyme in the phase II metabolism of arylamines and arylhydrazines. NAT2 is highly polymorphic, resulting in variable distributions of rapid and poor metabolizers across global populations. Here, we detail the process undertaken by the Clinical Pharmacogenetics Implementation Consortium (CPIC) NAT2 ...
Bailey M. Tibben, David W. Hein, Michelle Whirl‐Carrillo, Andrea Gaedigk, Michael T. Eadon, Rodney F. Minchin, Sotiria Boukouvala, Adalberto Rezende Santos, Roseann S. Donnelly, José A. G. Agúndez, Kelly E. Caudle   +10 more
wiley   +1 more source

Contemporary pharmacogenetic assays in view of the PharmGKB database [PDF]

, 2019
Aim: Six modern PGx assays were compared with the Pharmacogenomics Knowledge Base (PharmGKB) to determine the proportion of the currently known PGx genotypes that are assessed by these assays.
Deforce, Dieter, Weymaere, Jana0001203115248020026650119190267756400000-0002-8213-1973C81B15F8-F0EE-11E1-A197-91C894A0A6B4, Weymaere, Jana, Van Nieuwerburgh, FilipFW010019944544838010013358290000-0001-8815-5485F5BC58D8-F0ED-11E1-A9DE-61C894A0A6B4, Tilleman, LaurentijnDI040001100597358020023900740000-0001-7584-117933C35672-F0EE-11E1-A9DE-61C894A0A6B4, Heindryckx, BjörnGE38UZGent0019942807928010013427010000-0003-0630-8420F5C0698C-F0ED-11E1-A9DE-61C894A0A6B4, Deforce, DieterFW010019890795728010009626800000-0002-0635-661XF4D02620-F0ED-11E1-A9DE-61C894A0A6B4, Tilleman, Laurentijn, Heindryckx, Björn, Van Nieuwerburgh, Filip   +9 more
core   +1 more source

Knowledge, perceptions, and attitudes toward pharmacogenomics among pharmacists and pharmacy students: A systematic review

Health Science Reports
Background and Aims Pharmacists have been recognized as one of the most qualified healthcare professionals in the clinical implementation of pharmacogenomics, yet its widespread implementation in clinical pharmacy practice has remained limited.
Amanda Wondrasek, Amber Fryza, Md. Abdul Aziz, Christine Leong, Kaarina Kowalec, Abdullah Al Maruf   +5 more
doaj   +1 more source

Seminars in epileptology: Holistic management of epilepsy in adults with intellectual development disorders

Epileptic Disorders, EarlyView.
Abstract This seminar addresses the complexity of the management of epilepsy in adults with intellectual development disorders (IDD), advocating holistic and multidisciplinary care aligned with the learning objectives of the International League Against Epilepsy. Epilepsy is significantly more prevalent in people with IDD, presenting unique diagnostic,
Elena Fonseca, Antonella Riva, Samuel López‐Maza, Malin Zaddach, Marie‐Claire Porter, Ingo Borggraefe, Lance Watkins, Andreas Schulze‐Bonhage, Rohit Shankar, Pasquale Striano, Lina Nashef   +10 more
wiley   +1 more source

A translational multimodal machine‐learning prototype predicting valproate response in epilepsy treatment

Epilepsia, EarlyView.
Abstract Objective Epilepsy affects ~1% of the global population and often requires lifelong antiseizure medication (ASM) therapy. Valproic acid (VPA) is a commonly prescribed first‐line ASM, yet only approximately half of patients achieve sustained seizure freedom. Treatment selection remains largely empirical.
Simeon Platte, Afsheen Kumar, Giorgia Guerini, Massimo Pandolfo, Denise Haslinger, Colin B. Josephson, Guillermo Delgado‐García, Navprabhjot Kaur, Michaela‐Pauline Lux, Heiko Stempfle, Chantal Depondt, Reetta Kälviäinen, Felix Rosenow, Sophie von Brauchitsch, Karl Martin Klein, Andreas G. Chiocchetti   +15 more
wiley   +1 more source

Pharmacogenomics in Asia [PDF]

, 2004
http://dx.doi.org/10.1517/14622416.5.8 ...
Gushima, Hiroshi, Tamaoki, Mieko, Tsutani, Kiichiro   +2 more
core  

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source

Personalized medicine in breast cancer: pharmacogenomics approaches [PDF]

, 2019
Shabnam Jeibouei,1 Mohammad Esmael Akbari,2 Alireza Kalbasi,3 Amir Reza Aref,4,5 Mohammad Ajoudanian,6 Alireza Rezvani,7 Hakimeh Zali81Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical ...
Zali H, Jeibouei S, Aref AR, Akbari ME, Ajoudanian M, Kalbasi A, Rezvani A   +6 more
core  

Update on the pharmacogenomics of pain management

Pharmacogenomics and Personalized Medicine, 2019
Alan David Kaye,1 Andrew Jesse Garcia,2 O Morgan Hall,3 George M Jeha,4 Kelsey D Cramer,4 Amanda L Granier,4 Anusha Kallurkar,5 Elyse M Cornett,5 Richard D Urman61Department of Anesthesiology, LSU Health Sciences Center, New Orleans, LA, USA; 2Department
Kaye AD, Garcia AJ, Hall OM, Jeha GM, Cramer KD, Granier AL, Kallurkar A, Cornett EM, Urman RD   +8 more
doaj  

Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction

World Journal of Surgical Oncology
Background Non-small cell lung cancer (NSCLC) is a prevalent and heterogeneous disease with significant genomic variations between the early and advanced stages. The identification of key genes and pathways driving NSCLC tumor progression is critical for
Junpeng Cheng, Meizhu Xiao, Qingkang Meng, Min Zhang, Denan Zhang, Lei Liu, Qing Jin, Zhijin Fu, Yanjiao Li, Xiujie Chen, Hongbo Xie   +10 more
doaj   +1 more source